Management of the hospitalized patient with Parkinson's disease: Current state of the field and need for guidelines

Parkinsonism and Related Disorders

Volumn 17, Issue 3, 2011, Pages 139-145

  Aminoff, Michael J ^a   Christine, Chad W ^a   Friedman, Joseph H ^b   Chou, Kelvin L ^c   Lyons, Kelly E ^d   Pahwa, Rajesh ^d   Bloem, Bastian R ^e   Parashos, Sotirios A ^f   Price, Catherine C ^g   Malaty, Irene A ^g   Iansek, Robert ^h   Bodis Wollner, Ivan ⁱ   Suchowersky, Oksana ^j   Oertel, Wolfgang H ^k   Zamudio, Jorge ^l   Oberdorf, Joyce ^l   Schmidt, Peter ^l   Okun, Michael S ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f School of Human Environmental Sciences   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h National Parkinson Foundation Center of Excellence   (Australia)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l National Parkinson Foundation   (United States)

more..

Author keywords

Complications; Confusion; Fall; Fracture; Medication; Perioperative; Surgery

Indexed keywords

AMANTADINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; APOMORPHINE; DANTROLENE; FLUDROCORTISONE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPNOTIC AGENT; MIDODRINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOSTIGMINE; ROTIGOTINE; SPASMOLYTIC AGENT;

COST CONTROL; EDUCATION PROGRAM; FALLING; FRACTURE; HOSPITAL MANAGEMENT; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INAPPROPRIATE PRESCRIBING; MEDLINE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PEER REVIEW; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

HEALTH SERVICES NEEDS AND DEMAND; HOSPITALIZATION; HUMANS; PARKINSON DISEASE; PUBMED; TREATMENT OUTCOME;

EID: 79951557639     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.11.009     Document Type: Review

References (82)

1. Klein C., Prokhorov T., Miniovitz A., Dobronevsky E., Rabey J.M. Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm 2009 Nov, 116(11):1509-1512.
2. Mueller M.C., Juptner U., Wuellner U., Wirz S., Turler A., Hirner A., et al. Parkinson's disease influences the perioperative risk profile in surgery. Langenbecks Arch Surg 2009 May, 394(3):511-515.
3. Rhalimi M., Helou R., Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 2009, 26(10):847-852.
4. Chou K., Okun M.S., Fernandez H.H., Breslow D., Friedman J.H. Five frequently asked questions about hospitalization: For patients with Parkinson disease Summer 2007, The Parkinson Report, pp. 7-11.
5. Guttman M., Slaughter P.M., Theriault M.E., DeBoer D.P., Naylor C.D. Burden of Parkinsonism: a population-based study. Mov Disord 2003 Mar, 18(3):313-319.
6. Vossius C., Nilsen O.B., Larsen J.P. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand 2010 Jan, 121(1):38-43.
7. Woodford H., Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005 Sep, 20(9):1104-1108.
8. Parashos S.A., Maraganore D.M., O'Brien P.C., Rocca W.A. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002 Sep, 77(9):918-925.
9. Temlett J.A., Thompson P.D. Reasons for admission to hospital for Parkinson's disease. Intern Med J 2006 Aug, 36(8):524-526.
10. Louis E.D., Henchcliffe C., Bateman B.T., Schumacher C. Young-onset Parkinson's disease: hospital utilization and medical comorbidity in a nationwide survey. Neuroepidemiology 2007, 29(1-2):39-43.
11. Muller M.C., Juptner U., Wullner U., Wirz S., Turler A., Wirtz D.C., et al. Z Orthop Unfall 2008 Mar-Apr, 146(2):227-230.
12. Kipps C.M., Fung V.S., Grattan-Smith P., de Moore G.M., Morris J.G. Movement disorder emergencies. Mov Disord 2005 Mar, 20(3):322-334.
13. Adarraga Cansino M.D., Zambrana Garcia J.L., Velasco Malagon M.J., Rosa Jimenez F. Med Clin (Barc) 2004 Apr 3, 122(12):477.
14. Hashimoto T., Tokuda T., Hanyu N., Tabata K., Yanagisawa N. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord 2003 Apr, 9(Suppl. 1):S25-S30.
15. Miller N., Allcock L., Hildreth A.J., Jones D., Noble E., Burn D.J. Swallowing problems in Parkinson disease: frequency and clinical correlates. J Neurol Neurosurg Psychiatr 2009 Sep, 80(9):1047-1049.
16. Robbins J., Gensler G., Hind J., Logemann J.A., Lindblad A.S., Brandt D., et al. Comparison of 2 interventions for liquid aspiration on pneumonia incidence: a randomized trial. Ann Intern Med 2008 Apr 1, 148(7):509-518.
17. Wang X., You G., Chen H., Cai X. Clinical course and cause of death in elderly patients with idiopathic Parkinson's disease. Chin Med J (Engl) 2002 Sep, 115(9):1409-1411.
18. Fernandez H.H., Lapane K.L. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monit 2002 Apr, 8(4):CR241-CR246.
19. Miyazaki Y., Arakawa M., Kizu J. Introduction of simple swallowing ability test for prevention of aspiration pneumonia in the elderly and investigation of factors of swallowing disorders. Yakugaku Zasshi 2002 Jan, 122(1):97-105.
20. Troche M.S., Sapienza C.M., Rosenbek J.C. Effects of bolus consistency on timing and safety of swallow in patients with Parkinson's disease. Dysphagia 2008 Mar, 23(1):26-32.
21. Pitts T., Bolser D., Rosenbek J., Troche M., Okun M.S., Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest 2009 May, 135(5):1301-1308.
22. Pitts T., Bolser D., Rosenbek J., Troche M., Sapienza C. Voluntary cough production and swallow dysfunction in Parkinson's disease. Dysphagia 2008 Sep, 23(3):297-301.
23. Sapienza C.M., Wheeler K. Respiratory muscle strength training: functional outcomes versus plasticity. Semin Speech Lang 2006 Nov, 27(4):236-244.
24. Silverman E.P., Sapienza C.M., Saleem A., Carmichael C., Davenport P.W., Hoffman-Ruddy B., et al. Tutorial on maximum inspiratory and expiratory mouth pressures in individuals with idiopathic Parkinson disease (IPD) and the preliminary results of an expiratory muscle strength training program. NeuroRehabilitation 2006, 21(1):71-79.
25. Saleem A.F., Sapienza C.M., Okun M.S. Respiratory muscle strength training: treatment and response duration in a patient with early idiopathic Parkinson's disease. NeuroRehabilitation 2005, 20(4):323-333.
26. Cervo F.A., Bryan L., Farber S. To PEG or not to PEG: a review of evidence for placing feeding tubes in advanced dementia and the decision-making process. Geriatrics 2006 Jun, 61(6):30-35.
27. Zalar A.E., Guedon C., Piskorz E.L., Sanchez Basso A., Ducrotte P. Acta Gastroenterol Latinoam 2004, 34(3):127-132.
28. Doux M.M. Rev Infirm 1993 Mar, 43(5):43-45.
29. Ebihara S., Saito H., Kanda A., Nakajoh M., Takahashi H., Arai H., et al. Impaired efficacy of cough in patients with Parkinson disease. Chest 2003 Sep, 124(3):1009-1015.
30. Parker S.E., Nathwani D., O'Reilly D., Parkinson S., Davey P.G. Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimicrob Chemother 1998 Sep, 42(3):373-380.
31. Wermuth L., Stenager E.N., Stenager E., Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995 Jul, 92(1):55-58.
32. Nicholson P.W., Leeman A.L., O'Neill C.J., Dobbs S.M., Deshmukh A.A., Denham M.J., et al. Pressure sores: effect of Parkinson's disease and cognitive function on spontaneous movement in bed. Age Ageing 1988 Mar, 17(2):111-115.
33. Trosch R.M., Friedman J.H., Lannon M.C., Pahwa R., Smith D., Seeberger L.C., et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998 May, 13(3):377-382.
34. Khouzam H.R. Quetiapine in the treatment of postoperative delirium. A report of three cases. Compr Ther 2008, 34(3-4):207-217.
35. Chitnis S., Rao J. Rivastigmine in Parkinson's disease dementia. Expert Opin Drug Metab Toxicol 2009 Aug, 5(8):941-955.
36. Darreh-Shori T., Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf Jan 2010, 9(1):167-176.
37. Clubb V.J., Clubb S.E., Buckley S. Parkinson's disease patients who fracture their neck of femur: a review of outcome data. Injury 2006 Oct, 37(10):929-934.
38. Sato Y., Honda Y., Iwamoto J., Kanoko T., Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005 Dec, 20(12):1598-1603.
39. Sato Y., Kaji M., Tsuru T., Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001 Jan 1, 182(2):89-93.
40. Jamnadas-Khoda J., Koshy S., Mathias C.J., Muthane U.B., Ragothaman M., Dodaballapur S.K. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. Mov Disord 2009 Sep 15, 24(12):1747-1751.
41. Calne D.B. Diagnosis and treatment of Parkinson's disease. Hosp Pract (Off Ed) 1995 Jan 15, 30(1):83-86. 89.
42. Nozaki S., Kang J., Miyai I., Matsumura T. Rinsho Shinkeigaku 1993 Nov, 33(11):1135-1139.
43. Singer W., Sandroni P., Opfer-Gehrking T.L., Suarez G.A., Klein C.M., Hines S., et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006 Apr, 63(4):513-518.
44. Singer W., Opfer-Gehrking T.L., McPhee B.R., Hilz M.J., Bharucha A.E., Low P.A. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003 Sep, 74(9):1294-1298.
45. Zibetti M., Rosso M., Cinquepalmi A., Lanotte M., Angrisano S., Rabbia C., et al. Asymptomatic deep venous thrombosis after deep brain stimulation for Parkinson disease. Stereotact Funct Neurosurg 2010, 88(2):94-97.
46. Mosewich R.K., Rajput A.H., Shuaib A., Rozdilsky B., Ang L. Pulmonary embolism: an under-recognized yet frequent cause of death in parkinsonism. Mov Disord 1994 May, 9(3):350-352.
47. Hirsch D.R., Goldhaber S.Z. Laboratory parameters to monitor safety and efficacy during thrombolytic therapy. Chest 1991 Apr, 99(4 Suppl.):113S-120S.
48. Merims D., Balas M., Peretz C., Shabtai H., Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006 Nov-Dec, 29(6):331-337.
49. Rabey J.M., Prokhorov T., Miniovitz A., Dobronevsky E., Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007 Feb 15, 22(3):313-318.
50. Ondo W.G., Tintner R., Voung K.D., Lai D., Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005 Aug, 20(8):958-963.
51. Morgante L., Epifanio A., Spina E., Zappia M., Di Rosa A.E., Marconi R., et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004 Jul-Aug, 27(4):153-156.
52. Pollak P., Tison F., Rascol O., Destee A., Pere J.J., Senard J.M., et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatr 2004 May, 75(5):689-695.
53. Factor S.A., Feustel P.J., Friedman J.H., Comella C.L., Goetz C.G., Kurlan R., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003 Jun 10, 60(11):1756-1761.
54. Morgante L., Epifanio A., Spina E., Di Rosa A.E., Zappia M., Basile G., et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002 Sep, 23(Suppl. 2):S89-S90.
55. Factor S.A., Friedman J.H., Lannon M.C., Oakes D., Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001 Jan, 16(1):135-139.
56. Goetz C.G., Blasucci L.M., Leurgans S., Pappert E.J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000 Sep 26, 55(6):789-794.
57. Ellis T., Cudkowicz M.E., Sexton P.M., Growdon J.H. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000 Summer, 12(3):364-369.
58. The French Clozapine Parkinson Study Group Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999 Jun 12, 353(9169):2041-2042.
59. The Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999 Mar 11, 340(10):757-763.
60. Wolters E.C., Hurwitz T.A., Mak E., Teal P., Peppard F.R., Remick R., et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990 May, 40(5):832-834.
61. Miyasaki J.M., Shannon K., Voon V., Ravina B., Kleiner-Fisman G., Anderson K., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2006 Apr 11, 66(7):996-1002.
62. Fernandez H.H., Okun M.S., Rodriguez R.L., Malaty I.A., Romrell J., Sun A., et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009, 119(12):2196-2205.
63. Khouzam H.R., Emes R. Late life psychosis: assessment and general treatment strategies. Compr Ther 2007 Fall, 33(3):127-143.
64. Rabey J.M. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord 2009 Dec, 15(Suppl. 4):SS1105-SS1110.
65. Witjas T., Kaphan E., Azulay J.P., Blin O., Ceccaldi M., Pouget J., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002 Aug 13, 59(3):408-413.
66. Quelhas R., Costa M. Anxiety, depression, and quality of life in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2009 Fall, 21(4):413-419.
67. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Buyske S., et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009 Mar 10, 72(10):886-892.
68. Manor Y., Balas M., Giladi N., Mootanah R., Cohen J.T. Anxiety, depression and swallowing disorders in patients with Parkinson's disease. Parkinsonism Relat Disord 2009 Jul, 15(6):453-456.
69. Aarsland D., Pedersen K.F., Ehrt U., Bronnick K., Gjerstad M.D., Larsen J.P. Tidsskr Nor Laegeforen 2008 Sep 25, 128(18):2072-2076.
70. Stern M.B. Electroconvulsive therapy in untreated Parkinson's disease. Mov Disord 1991, 6(3):265.
71. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T.P., et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009 Aug 15, 24(11):1641-1649.
72. Schneider F., Althaus A., Backes V., Dodel R. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008 Nov, 258(Suppl. 5):55-59.
73. Strecker K., Schwarz J. Parkinson's disease: emerging pharmacotherapy. Expert Opin Emerg Drugs 2008 Dec, 13(4):573-591.
74. Cosentino M., Martignoni E., Michielotto D., Calandrella D., Riboldazzi G., Pacchetti C., et al. Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Serv Res 2005 Mar 24, 5(1):26.
75. Pepper P.V., Goldstein M.K. Postoperative complications in Parkinson's disease. J Am Geriatr Soc 1999 Aug, 47(8):967-972.
76. Ellis T., Katz D.I., White D.K., DePiero T.J., Hohler A.D., Saint-Hilaire M. Effectiveness of an inpatient multidisciplinary rehabilitation program for people with Parkinson disease. Phys Ther 2008 Jul, 88(7):812-819.
77. Klawans H.L., Goetz C.G., Tanner C.M., Nausieda P.A., Weiner W.J. Levodopa-free periods (" drug holidays" ) in the management of parkinsonism. Adv Neurol 1983, 37:33-43.
78. Zuckerman L.M. Parkinson's disease and the orthopaedic patient. J Am Acad Orthop Surg 2009 Jan, 17(1):48-55.
79. Mehta S., Vankleunen J.P., Booth R.E., Lotke P.A., Lonner J.H. Total knee arthroplasty in patients with Parkinson's disease: impact of early postoperative neurologic intervention. Am J Orthop (Belle Mead NJ) 2008 Oct, 37(10):513-516.
80. Queally J.M., Abdulkarim A., Mulhall K.J. Total hip replacement in patients with neurological conditions. J Bone Joint Surg Br 2009 Oct, 91(10):1267-1273.
81. Idjadi J.A., Aharonoff G.B., Su H., Richmond J., Egol K.A., Zuckerman J.D., et al. Hip fracture outcomes in patients with Parkinson's disease. Am J Orthop (Belle Mead NJ) 2005 Jul, 34(7):341-346.
82. Morishita T., Foote K.D., Burdick A.P., Katayama Y., Yamamoto T., Frucht S.J., et al. Identification and management of deep brain stimulation intra- and postoperative urgencies and emergencies. Parkinsonism Relat Disord Mar 2010, 16(3):153-162.